Gencurix's study explores GenesWell BCT and Oncotype DX differences

We are very pleased and excited to announce the "opening" of a totally redesigned websites for GENCURIX and GenesWell BCT. ​ Gencurix corporate website is to provide a comprehensive information of the company and GenesWell BCT website is dedicated in highlighting its characteristics, clinical information and test process. Both websites will continuously evolve and new...

South Korea has transformed from a COVID-19 hot zone to a leader in the global fight against the virus. Companies there are now making millions of test kits for export, and the public is voting in a parliamentary election despite the disease. Special correspondent Bruce Harrison reports from Seoul on how South Koreans have worked together to make progress -- and aim to p...

GenesWell BCT is a prognostic test that makes the prognosis of other cancer metastasis and recurrence within 10 years, by analyzing the expression levels of six cancer prognostic genes and three standard genes extracted from the RNA of cancer tissues removed during surgery of breast cancer patients. The study, led by Kyungpook National University Hospital, compared th...